Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
12 affiliations
- 1Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III & Center for Healthy Aging, Medical Faculty and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
- 2Else Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
- 3Medizinische Universität Lausitz – Carl Thiem, Cottbus, Germany
- 4Digital Health Cluster, Department for Digital Health, Economics & Policy, Hasso-Plattner Institute, University of Potsdam, Potsdam, Germany
- 5Department of Medicine I, Medical Faculty and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
- 6German Cancer Consortium (DKTK), Partner Sites Dresden and Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany
- 7Department of Hematology, Cell Therapy, Hemostaseology, and Infectious Diseases, University Hospital, Leipzig, Germany
- 8Department of Medicine III, Technical University of Munich, School of Medicine and Health, Munich, Germany
- 9Department of Orthopedic Surgery, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
- 10Division of Orthopedic, Trauma and Plastic Surgery, University Hospital, Leipzig, Germany
- 11Faculty of Medicine Carl Gustav Carus, Institute for Medical Informatics and Biometry, Dresden University of Technology, Dresden, Germany
- 12Center for Evidence-Based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
Abstract
Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bone and Hematology in Elderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS (n = 111; 36% female) and age-matched controls (n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05]. Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05]. The presence of osteoporosis was associated with poor overall survival in MDS [p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
Related
- UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials
- Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
- Persistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms
- Somatic DDX41 mutations confer neomorphic splicing activity in the pathogenesis of myelodysplastic neoplasms
- Elevated Maternal Glycated Albumin is Associated with Large for Gestational Age Infants: Results from a Prospective Longitudinal Study
BibTeX
@article{weidner2026bone,
title = {{Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study}},
author = {Heike Weidner and Elena Tsourdi and Anne Sophie Platzbecker and Martina Rauner and Ulrike Baschant and Maria G. Ledesma-Colunga and Karolina Basiak and Katja Sockel and Ekaterina Balaian and Susann Winter and Anna Harig and Klaus H. Metzeler and Katharina S. Götze and Dominic Brauer and Nicole Modler and Michael Cross and Marie Schneider and Jörg Lützner and Andreas Roth and Thomas Zerjatke and Gabriele Müller and Uwe Platzbecker and Lorenz C. Hofbauer},
journal = {Leukemia},
year = {2026},
month = oct,
doi = {10.1038/s41375-026-03125-8},
url = {https://doi.org/10.1038/s41375-026-03125-8},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
AU - Heike Weidner
AU - Elena Tsourdi
AU - Anne Sophie Platzbecker
AU - Martina Rauner
AU - Ulrike Baschant
AU - Maria G. Ledesma-Colunga
AU - Karolina Basiak
AU - Katja Sockel
AU - Ekaterina Balaian
AU - Susann Winter
AU - Anna Harig
AU - Klaus H. Metzeler
AU - Katharina S. Götze
AU - Dominic Brauer
AU - Nicole Modler
AU - Michael Cross
AU - Marie Schneider
AU - Jörg Lützner
AU - Andreas Roth
AU - Thomas Zerjatke
AU - Gabriele Müller
AU - Uwe Platzbecker
AU - Lorenz C. Hofbauer
PY - 2026
DA - 2026/10/09
JO - Leukemia
DO - 10.1038/s41375-026-03125-8
UR - https://doi.org/10.1038/s41375-026-03125-8
AB - Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bone and Hematology in Elderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS (n = 111; 36% female) and age-matched controls (n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05]. Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05]. The presence of osteoporosis was associated with poor overall survival in MDS [p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
SN - 0887-6924
SN - 1476-5551
ER -